Study of the effect of a drug from the macromycetes Ganoderma lucidum on the phagocytic activity of peripheral blood neutrophils in patients with year-round allergic rhinitis
DOI:
https://doi.org/10.12775/JEHS.2024.62.005Keywords
allergic rhinitis, phagocytic activity of neutrophils, macromycetes Ganoderma lucidumAbstract
Modern complex therapy of patients with persistent (year-round, chronic) allergic rhinitis (AR), based on the use of antihistamines and intranasal glucocorticosteroids, in many cases is not effective enough, since drug therapy acts only on individual links in the pathogenesis, without preventing the progression of the allergic disease. At the same time, the quantitative and reserve capabilities of neutrophil granulocytes are depleted, which increases the level of antigenic load in patients with AR. The aim of this study is to investigate the phagocytic activity of neutrophils in patients with AR who received basic therapy and patients who received basic therapy and a course of the drug from the macromycetes Ganoderma lucidum "Astmagan". We examined 40 patients of both sexes with AR, the duration of the disease ranged from 6 months to 2 years. Patients were divided into 2 equal groups: The 1st group consisted of patients who received basic therapy (oral Loratadine and intranasal Nasonex). The 2nd group consisted of patients who received basic therapy and a course of "Astmagan". The treatment course lasted 90 days. The control group consisted of 25 healthy individuals. After the treatment, patients in both groups showed a statistically significant positive dynamics of phagocytic system activity: in group 1, the phagocytic index (FI) increased by 30 % (p=0.001), in the second group this indicator reached the normal level. Also, in patients of group 1, the phagocytic number (PN) increased by 35 % (p=0.0001), but did not reach the normal level.
According to the results of comparative evaluation, a greater efficacy of the treatment complex with the additional use of "Astmagan" was established, which is manifested in the restoration of phagocytic activity of peripheral blood neutrophils, the effect persists for 6 months after treatment.
References
Cingi C, Gevaert P, Mösges R. Rondon C, Hox V et al. Multi-morbidities of allergic rhinitis in adults: European Academy of Allergy and Clinical Immunology Task Force Report. Clin Transl Allergy. 2017;7:17. DOI: 10.1186/s13601-017-0153-z
Larsen J, Broge L, Jacobi H. Allergy immunotherapy: the future of allergy treatment. 2016;21(1):26-37.DOI: https://doi.org/10.1016/j.drudis.2015.07.010
Arcimowicz M. Allergic rhinitis - effective treatment according to the latest recommendations. Otolaryngol Pol. 2022 Dec 15;76(6):45-59. DOI: 10.5604/01.3001.0016.1488
Ahmad F, Alsayegh АА, Ahmad FA, Akhtar S, Alavudeen SS et al. Ganoderma lucidum: Insight into antimicrobial and antioxidant properties with development of secondary metabolites. Heliyon. 2024:e25607. DOI: https://doi.org/10.1016/j.heliyon.2024.e25607
Lu J, He R, Sun P, Zhang F, Linhardt RJ et al. Molecular mechanisms of bioactive polysaccharides from Ganodermalucidum (Lingzhi), a review.Int J BiolMacromol. 2020 May 1:150:765-774. DOI: 10.1016/j.ijbiomac.2020.02.035
Seweryn E, Ziała A, Gamian A. Health-Promoting of Polysaccharides Extracted from Ganoderma lucidum. Nutrients. 2021 Aug 7;13(8):2725. DOI: 10.3390/nu13082725
Bhardwaj N, Katyal P, Sharma AK. Suppression of inflammatory and allergic responses by pharmacologically potent fungus Ganoderma lucidum. Recent Pat Inflamm Allergy Drug Discov. 2014;8(2):104-17. DOI: 10.2174/1872213x08666140619110657
Zhou X, Lin J, Yin Y, Zhao J, Sun X, Tang K. Ganodermataceae: natural products and their related pharmacological functions. Review Am J Chin Med. 2007;35(4):559-574. https://doi.org/10.1142/S0192415X07005065
Zeng P, Guo Z, Zeng X, Hao C, Zhang Y et al. Chemical, biochemical, preclinical and clinical studies of Ganoderma lucidum polysaccharide as an approved drug for treating myopathy and other diseases in China. J Cell Mol Med. 2018;22(7):3278-3297. DOI: 10.1111/jcmm.13613
Nagai K, Ueno Y, Tanaka S, Hayashi R, Shinagawa K, Chayama K. Polysaccharides derived from Ganoderma lucidum fungus mycelia ameliorate indomethacin-induced small intestinal injury via induction of GM-CSF from macrophages. Cell Immunol. 2017;320:20-28. DOI: 10.1016/j.cellimm.2017.08.001
Ahmad MF, Ahmad FA, Zeyaullah M, Alsayegh AA, Mahmood SE et al. Ganoderma lucidum: Novel Insight into Hepatoprotective Potential with Mechanisms of Action. Nutrients. 2023;15(8):1874. DOI: 10.3390/nu15081874
Chen TQ, Wu JG, Kan YJ, Yang C, Wu YB, Wu JZ. Antioxidant and Hepatoprotective Activities of Crude Polysaccharide Extracts from Lingzhi or Reishi Medicinal Mushroom, Ganodermalucidum (Agaricomycetes), by Ultrasonic-Circulating Extraction. Int J Med Mushrooms. 2018;20(6):581-593. DOI: 10.1615/IntJMedMushrooms.2018026536
Celal B. Antioxidant and antimicrobial capacities of Ganodermalucidum. J BacteriolMycol Open Access. 2019;7(1):5-7. DOI: 10.15406/jbmoa.2019.07.00232
Cör Andrejč D, Knez Ž, Knez Marevci M. Antioxidant, antibacterial, antitumor, antifungal, antiviral, anti-inflammatory, and nevro-protective activity ofGanodermalucidum: An overview. Front Pharmacol. 2022 Jul 22;13:934982. DOI: 10.3389/fphar.2022.934982
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 V. Bohdanov, S. Gushcha
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 311
Number of citations: 0
